Full Text View
Tabular View
No Study Results Posted
Related Studies
Memantine Treatment of Compulsive Buying
This study is currently recruiting participants.
Verified by University of Minnesota, March 2009
First Received: January 23, 2009   Last Updated: March 16, 2009   History of Changes
Sponsored by: University of Minnesota
Information provided by: University of Minnesota
ClinicalTrials.gov Identifier: NCT00830375
  Purpose

This is an 8-week, open-labe study of memantine in the treatment of compulsive buying.


Condition Intervention Phase
Compulsive Buying
Drug: Memantine
Phase II

Drug Information available for: Memantine Memantine hydrochloride
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Dose Comparison, Single Group Assignment, Safety/Efficacy Study
Official Title: Memantine Treatment of Compulsive Buying: An Open-Label Study

Further study details as provided by University of Minnesota:

Primary Outcome Measures:
  • Yale Brown Obsessive Compulsive Scale Modified for CB (CB-YBOCS) [ Time Frame: from study start to study end (8-weeks) ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Compulsive Buying Symptom Assessment Scale (CB-SAS) [ Time Frame: from study start to end (8-weeks) ] [ Designated as safety issue: No ]
  • Clinical Global Impression-Improvement and Severity scales (CGI) [ Time Frame: from study start to end (8-weeks) ] [ Designated as safety issue: No ]

Estimated Enrollment: 16
Study Start Date: December 2008
Estimated Study Completion Date: November 2009
Estimated Primary Completion Date: October 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Memantine: Experimental
10-30mg, memantine
Drug: Memantine
10-30mg, by mouth, daily

Detailed Description:

The goal of the proposed study is to evaluate the efficacy of memantine in the treatment of compulsive buying. Sixteen subjects meeting criteria for compulsive buying will receive 8 weeks of open-label memantine. The hypothesis to be tested is that memantine will be effective and well tolerated in patients with compulsive buying. The proposed study will provide needed data on the treatment of a disabling disorder that currently lacks a clearly effective treatment.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. men and women age 18-65
  2. current CB using the clinician-administered Structured Clinical Interview for Compulsive buying (SCI-CB)
  3. buying behavior within 2 weeks prior to enrollment

Exclusion Criteria:

  1. infrequent buying (i.e. less than one time per week) that does not meet proposed criteria for CB
  2. unstable medical illness or clinically significant abnormalities on laboratory tests or physical examination at screen
  3. history of seizures
  4. myocardial infarction within 6 months
  5. current pregnancy or lactation, or inadequate contraception in women of childbearing potential
  6. a need for medication other than memantine with possible psychotropic effects or unfavorable interactions;
  7. clinically significant suicidality;
  8. current Axis I disorder determined by the SCID and SCID-compatible modules for impulse control disorders, except for nicotine dependence
  9. lifetime history of bipolar disorder type I or II, dementia, schizophrenia, or any psychotic disorder determined by SCID
  10. current or recent (past 3 months) DSM-IV substance abuse or dependence;
  11. positive urine drug screen at screening
  12. initiation of psychotherapy or behavior therapy within 3 months prior to study baseline
  13. previous treatment with memantine
  14. treatment with investigational medication or depot neuroleptics within 3 months, with fluoxetine within 6 weeks, or with other psychotropics within 2 weeks prior to study baseline
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00830375

Contacts
Contact: Brian Odlaug, BA 612-627-4363 odla0019@umn.edu
Contact: Jon Grant, MD 612-273-9736 grant045@umn.edu

Locations
United States, Minnesota
University of Minnesota Recruiting
Minneapolis, Minnesota, United States, 55454
Contact: Brian Odlaug, BA     612-627-4363     odla0019@umn.edu    
Contact: Jon Grant, MD     612-273-9736     grant045@umn.edu    
Principal Investigator: Jon Grant, MD            
Sub-Investigator: SW Kim, MD            
Ambulatory Research Center Recruiting
Minneapolis, Minnesota, United States, 55454
Contact: Brian L Odlaug, B.A.     612-627-4363     odla0019@umn.edu    
Principal Investigator: Jon E Grant, M.D.            
Sponsors and Collaborators
University of Minnesota
Investigators
Principal Investigator: Jon Grant, MD University of Minnesota
  More Information

Additional Information:
No publications provided

Responsible Party: University of Minnes0ta ( Jon E. Grant, MD )
Study ID Numbers: 0806M37821
Study First Received: January 23, 2009
Last Updated: March 16, 2009
ClinicalTrials.gov Identifier: NCT00830375     History of Changes
Health Authority: United States: Food and Drug Administration

Keywords provided by University of Minnesota:
Buying
Shopping
Impulse Control

Study placed in the following topic categories:
Excitatory Amino Acids
Neurotransmitter Agents
Dopamine
Memantine
Dopamine Agents

Additional relevant MeSH terms:
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Anti-Dyskinesia Agents
Therapeutic Uses
Physiological Effects of Drugs
Antiparkinson Agents
Memantine
Excitatory Amino Acid Agents
Dopamine Agents
Central Nervous System Agents
Pharmacologic Actions
Excitatory Amino Acid Antagonists

ClinicalTrials.gov processed this record on May 06, 2009